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Abstract
Rationale Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis has been widely reported in depression, and evidence
suggests that selective serotonin reuptake inhibitors (SSRIs) might exert their therapeutic effects through altering cortisol
secretion.
Objective This study assessed the effects of SSRI administration on diurnal cortisol secretion in healthy volunteers.
Methods Sixty-four healthy men and women were randomised to receive either 10 mg escitalopram or placebo for six days in a
double-blind fashion. On day six of medication, saliva samples were obtained at home for measurement of diurnal cortisol
parameters (cortisol slope, cortisol awakening response, total daily cortisol output).
Results Women receiving escitalopram had significantly steeper cortisol slopes across the day compared with those receiving
placebo (F(1, 36) = 7.54, p = 0.009). This alteration in cortisol slope was driven by increases in waking cortisol levels (F(1, 35) =
9.21, p = 0.005). Escitalopram did not have any significant effect on the cortisol awakening response or the total daily cortisol
output.
Conclusions Flattened cortisol slopes have been seen in depression. The results of this study suggest that escitalopram might
exert its therapeutic effect in women in part through correction of a flattened diurnal cortisol rhythm.
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Introduction
Depression is one of the most common stress-related disorders.
A deficit in serotonergic activity is part of the neurobiology of
depression. Hyperactivity of the hypothalamic-pituitary-adrenal
(HPA) axis has also been widely reported in major depression
(Otte et al. 2016). There is evidence that the abnormalities of
the serotonergic system and the HPA axis are linked and this
interaction may be an important mechanism involved in the de-
velopment of depression (Porter et al. 2004).
Cortisol is the endpoint of the HPA axis and is the major
circulating glucocorticoid in humans. Studies examining the
effects of selective serotonin reuptake inhibitors (SSRIs) on
cortisol levels have produced varied results. In healthy and
depressed participants, short- and longer-term SSRI adminis-
tration has brought about both increases (Ljung et al. 2001;
Sagud et al. 2002) and decreases in basal cortisol levels
(Jazayeri et al. 2010; Ahmed et al. 2011; Hernandez et al.
2013; Dziurkowska et al. 2013; Park et al. 2015), and some
studies have reported null effects (Mück-Seler et al. 2002;
Deuschle et al. 2003; Kauffman et al. 2005). These findings
suggest interaction between SSRIs and the HPA axis but allow
us to infer very little about the direction of the effect.
These mixed findings likely relate to issues of cortisol mea-
surement. A recent meta-analysis examining changes in cortisol
secretion as a predictor of anti-depressant response has shown that
results largely depend on the methodological quality of the study,
with the timing and method of cortisol measurement being of
* Amy Ronaldson
a.ronaldson@ucl.ac.uk
1 Research Department of Behavioural Science and Health, University
College London, 1-19 Torrington Place, London WC1E 6BT, UK
2 Department of Clinical Pharmacology, William Harvey Research
Institute, Queen Mary University of London, John Vane Science




great importance (Fischer et al. 2017). Cortisol secretion has a
marked diurnal pattern. Cortisol is at high levels on waking,
followed by a rise that reaches a peak approximately 30 min after
waking. This is referred to as the cortisol awakening response
(CAR). There is then a subsequent decline across the day, with
cortisol reaching its nadir at around midnight (Adam and Kumari
2009). However, to date, studies have largely relied on single
measurements of cortisol taken at varying times across the day.
Failure to take the diurnal patterning of cortisol secretion into
account makes it difficult to make inferences about the effects
of SSRIs on HPA axis function. Sampling cortisol several times
across the day allows for the measurement of the diurnal cortisol
profile and a more in-depth investigation of the involvement of
the HPA axis.
Dysregulation of the HPA axis can be due to a reduction in
the amplitude of the diurnal pattern (i.e., a flatter slope across
the day), a blunted or exaggerated CAR, or changes in total
daily cortisol output (area under the curve (AUC)).
Dysregulation of HPA axis function has been reported in de-
pression. Depressed patients have been found to have both
blunted and heightened CARs (Dedovic and Ngiam 2015),
increased AUC (Dienes et al. 2013; Marchand et al. 2014;
Boggero et al. 2017), and flatter diurnal cortisol slopes
(Adam et al. 2017). It is possible that SSRIs exert their thera-
peutic effects through ‘normalising’ dysregulation of the diur-
nal pattern of the HPA axis seen in depression. However, very
few studies have examined this. In patients with major depres-
sive disorder (MDD), and in first-degree relatives of depressed
patients, longer-term administration of SSRIs has been found
to decrease cortisol AUC and decrease waking cortisol levels
(Hinkelmann et al. 2012; Knorr et al. 2012; Ruhé et al. 2015).
This small body of work suggests that SSRI treatment affects
the pattern of diurnal cortisol secretion in depressed patients
and those at risk of depression. However, some of the studies
cited above report symptom remission alongside SSRI-
induced alterations in diurnal cortisol secretion (Hinkelmann
et al. 2012; Ruhé et al. 2015). In addition, studying this asso-
ciation in depressed patients may be confounded by symptom-
atic features of the disease, medications, and clinical history.
This means that we cannot distinguish whether observed
changes in cortisol secretion are due to symptomatology or
direct biological effects of serotonergic alterations on HPA
axis function. To date, only one study has assessed the effects
of SSRI administration on diurnal cortisol secretion in healthy
volunteers. In this study, short-term administration of SSRIs
brought about increases in waking cortisol levels (Harmer
et al. 2003), in direct opposition to the effects seen in patients
with depression. However, Harmer et al. (2003) did not report
on other parameters of diurnal cortisol secretion known to be
important in depression (Adam et al. 2017).
Therefore, the aim of the current study is to assess the
effects of short-term SSRI administration on several aspects
of diurnal HPA axis function in healthy volunteers. We
hypothesise that six-day administration of the SSRI
escitalopram will bring about alterations in the CAR, the cor-
tisol AUC, and the cortisol slope. However, we are unable to
hypothesise about the direction of these alterations as this
study is the first to explore the effects of SSRIs on these
cortisol parameters in non-depressed people. Harmer et al.
(2003) observed increases in waking cortisol after six-day
administration of citalopram in healthy volunteers.
Therefore, we hypothesise that escitalopram will bring about
the same increase in our participants. Sex is known to be an
important confounder when it comes to examining stress-
related disease (Bale and Epperson 2015), and women show
greater HPA axis reactivity to stress compared to men (Goel
et al. 2014). Depression is more prevalent in women (Otte
et al. 2016), and women have been found to be more respon-
sive to SSRIs than men (Khan et al. 2005). Therefore, in this
study, we will also examine how sex influences the effects of
SSRIs on diurnal HPA axis function.
Materials and methods
Participants and design The data used in this analysis were
collected as part of the Stress Pathways Study. The Stress
Pathways Study was a randomised, double-blind, placebo-
controlled trial designed to assess the effects of seven-day admin-
istration of pharmacological probes on the stress response in
healthy volunteers. All data were collected with the written in-
formed consent of the participants. Ethical approval was obtained
from the UCL Research Ethics Committee.
Participants were 70 healthy volunteers who were recruited
from UCL campus. Participants were randomised to receive
either 10 mg escitalopram (SSRI) or placebo every morning
after breakfast for seven days. The seven-day study period
was chosen, as escitalopram is known to exert therapeutic
effects in patients with depression by the end of one week of
treatment (Montgomery et al. 2001; Taylor et al. 2006). Saliva
samples were provided at home for diurnal cortisol measure-
ment on day six of placebo/escitalopram administration.
Participants had to be generally healthy, aged 18–65 years
and not taking any medications regularly (excluding the con-
traceptive pill). Specific exclusion criteria included any chron-
ic haematological, inflammatory, pulmonary, liver, renal, gas-
trointestinal, heart, cerebrovascular, and psychiatric disease;
any history of thromboembolism; and any current infection.
Participants who suffered from asthma, who had known aller-
gies to the study medications, previous gastrointestinal bleed-
ings, or who were pregnant or breastfeeding were excluded.
Only patients with blood pressure in the normal range were
included (90/60 to 140/90 mmHg).
We carried out analyses on 64 participants who successful-
ly provided saliva samples on day six (32 escitalopram, 32
placebo). Of the six participants excluded from the analysis,
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three failed to return the saliva samples (all placebo), and three
dropped out due to side effects (all escitalopram).
Study protocol Study participants came to a brief session
where they had their body composition measured and com-
pleted a questionnaire containing demographic and psychoso-
cial measures. Participants then received the study medication
and were instructed to take one capsule every morning after
breakfast for the following seven days. Participants were ad-
vised not to take any other medications or herbal remedies
while taking part in the study and to avoid alcohol and vigor-
ous physical activity. Participants were also provided with a
saliva sampling kit to be used at home in order to analyse
diurnal cortisol secretion. The following morning participants
began taking the medication. On day six of medication, saliva
sampling for the measurement of diurnal cortisol secretion
took place. Participants were recruited in a manner which
ensured that saliva sampling always took place on a weekday.
Diurnal salivary cortisol The saliva kit included seven pre-
labelled ‘salivette’ collection tubes (Sarstedt, Leicester, UK)
and a cortisol diary. The cortisol diary contained instructions
on how and when to give samples. These diaries were also
used to record information on factors likely to introduce var-
iation in cortisol samples such as mood, exercise, and daily
stressors. Participants provided seven saliva samples over the
course of a weekday: on waking, 30 min after waking (30+),
10 a.m., noon, 4 p.m., 8 p.m., and bedtime. Participants stored
their sample in the refrigerator before returning them to the
laboratory at UCL. Cortisol levels were assessed from saliva
using a time-resolved immunoassay with fluorescence detec-
tion at the University of Dresden. Inter- and intra-assay vari-
ability was below 4%.
Following analysis, three different indices of diurnal HPA
axis function were calculated for each participant: CAR, cor-
tisol AUC, and cortisol slope across the day. The CAR was
calculated by subtracting the waking from the + 30-min
values. When calculating the CAR, we omitted individuals
who reported a delay of > 15 min between waking and taking
the ‘waking’ sample (Dockray et al. 2008). We computed the
cortisol AUC with respect to ground (Pruessner et al. 2003).
The cortisol slope was calculated in nanomoles per litre per
minute (nmol/L/min) by regressing cortisol on sample collec-
tion time, with + 30 min excluded; higher values indicate a
steeper decrease in cortisol over the day. Waking and evening
(the average of 8 p.m. and bedtime) values were also calculat-
ed. As there were missing cortisol samples for some partici-
pants, the sample size for each analysis differed (Table 2).
Stress-related psychological factors Depressive symptoms,
anxiety, and positive affect were measured at baseline and
the day after diurnal salivary cortisol collection (day seven).
Depressive symptoms were measured using the Beck
Depression Inventory (BDI)-II (Beck et al. 1988). The
Cronbach’s alpha for the BDI-II in this sample was 0.87 at
baseline. Anxiety was measured using the anxiety subscale of
the Hospital Anxiety and Depression Scale (HADS)
(Zigmond and Snaith 1983). The Cronbach’s alpha for the
HADS anxiety subscale at baseline was 0.83. Positive affect
was measured using the positive subscale of the Positive and
Negative Affect Scale (PANAS) (Watson et al. 1988). The
Cronbach’s alpha for the positive affect scale was 0.83 at
baseline.
Demographic factors Age, sex, ethnicity, BMI, smoking sta-
tus, and level of parental education were measured in all par-
ticipants. Hormonal contraceptive use was measured in wom-
en. As the majority of participants were students, parental
education was used as an indicator of socioeconomic status
(SES). Smoking status was measured as a binary variable
(current smoker/non-smoker). BMI was calculated using the
standard formula (kg/m2).
Statistical analyses Normality tests revealed that all cortisol
parameters were normally distributed. Two-way ANOVAs
and chi-square tests were used to compare the medication
groups on all demographic characteristics. Where relevant,
sex was included as a between-person factor alongside medi-
cation. Changes in stress-related psychological factors were
assessed using two-way ANCOVAs, with medication and
sex as between-person factors, and baseline values being in-
cluded as covariates. Differences between the two medication
groups on all diurnal cortisol parameters were analysed using
two-way ANCOVAs, with medication and sex being included
as between-person factors. We examined the main effects of
medication as well as the interactive effect of sex.Where there
were significant interaction effects of sex on diurnal cortisol
parameters, we repeated the analyses in men and women sep-
arately. The significance level was set to p < 0.05 for all anal-
yses, with precise p values reported for all test results. All
statistical analyses were performed using SPSS version 22.0
(SPSS Inc., Chicago, IL, USA).
Results
Participants Table 1 summarises the characteristics of the par-
ticipants. The sample had an age range of 18–33 years, were
almost two-thirds women (62.5%), and were mostly normal
weight (79.7% BMI < 25). Over half the sample were white
(53.1%), and the majority of participants had a high SES
based upon parental education (84.4%).
Scores on the BDI-II at baseline ranged from 0 to 31 indicat-
ing the presence of depression in some participants. One partic-
ipant (escitalopram) had a BDI-II score greater than 19 indicating
the presence of probable clinical depression. Scores on the
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HADS anxiety subscale at baseline ranged from 0 to 15 indicat-
ing the presence of probable anxiety in some participants. Five
participants had scores of 11 or greater indicating anxiety (one
escitalopram; four placebo). Sensitivity analyses were carried out
with these participants removed (n= 5). Exclusion of these par-
ticipants did not affect the results of the study.
The escitalopram group did not differ significantly from the
placebo group in terms of sex, BMI, smoking status, ethnicity, or
SES (see Table 2 for all p values). There were also no significant
differences between groups in baseline depression scores, anxiety
scores, or positive affect scores. Amongst female participants,
there was no significant difference between experimental condi-
tions in terms of hormonal contraception use. There was a sig-
nificant interaction between medication group and sex with re-
spect to age (F(1, 60) = 5.60, p= 0.021), with differences in age
in men but not women. Men in the escitalopram group were
younger (M = 20.06 years, SD= 0.63 years) than men receiving
placebo (M= 22.44 years, SD= 0.81 years).
Stress-related psychological factors We investigated the ef-
fects of the study medications on depression, anxiety, and
positive affect on the seventh day of administration. This
was in order to clarify that any differences in diurnal cortisol
parameters between drug groups on the sixth study day were
not caused by changes in stress- or mood-related factors. The
escitalopram group did not differ from the placebo group in
depression scores, anxiety scores, or positive affect (see
Table 1). There were also no main or interactive effects of
sex on any of these factors.
Diurnal cortisol parameters There was no main effect of med-
ication and no main or interactive effect of sex on cortisol
AUC (all p values > 0.05). There was also no main effect of
medication or interactive effect of sex on the CAR (all p values
> 0.05). However, there was a main effect of sex on the CAR
(F(1, 48) = 4.62, p = 0.037). Women had more pronounced
CARs than men, regardless of medication group (Women:
M = 13.19 nmol/L, SE = 2.39 nmol /L; Men: M =
5.03 nmol/L, SE = 2.95 nmol/L).
There was no main effect of medication (p= 0.38) or sex (p=
0.12) on cortisol slope. However, the ANOVA revealed a signif-
icant medication group by sex interaction effect on cortisol slope
(F(1, 58) = 5.49, p= 0.023). Analysing male and female partici-
pants separately revealed no effect of medication on cortisol slope
in men (p= 0.40). However, there was an effect of medication in
women (F(1, 36) = 7.54, p= 0.009). Women taking escitalopram
had steeper cortisol slopes (M = 0.033 nmol/L/min, SD =
0.017 nmol/L/min) compared with women receiving placebo
(M= 0.014 nmol/L/min, SD=0.023 nmol/L/min) (Fig. 1).
Alterations in cortisol slope can be driven by levels of
cortisol at waking and/or in the evening. Therefore, we exam-
ined the effect of escitalopram on waking and evening cortisol
levels in female participants. There was a significant main
effect of medication on cortisol waking values (F(1, 35) =
9.21, p = 0.005), with levels being higher in female partici-
pants taking escitalopram (M = 30.44 nmol/L, SD =
9.39 nmol/L) than placebo (M = 18.57 nmol/L, SD =
13.31 nmol/L). There was no main effect of medication on
cortisol evening values (p = 0.13). What these findings
Table 1 Demographic characteristics of the sample (n = 64)
Escitalopram (n = 32) Placebo (n = 32) Escitalopram vs. placebo
Characteristic Mean ± SD or N (%) Mean ± SD or N (%) Group p value Group × sex p value
Age (years) 22.06 ± 3.89 22.22 ± 3.00 0.692 0.021*
Female 17(53.1) 23(71.9) 0.121 –
BMI (kg/m2) 23.26 ± 4.17 23.20 ± 4.01 0.757 0.267
Smoker 9(28.1) 4(12.5) 0.120 –
Ethnicity (White) 17(53.1) 17(53.1) 0.955 –
SES (n = 64) 0.853 –
Low 3(9.4) 3(9.4) – –
Medium 1(3.1) 2(6.3) – –
High 27(84.4) 27(84.4) – –
Hormonal contraception 7(41.2) 5(21.7) 0.304 –
Depressive symptoms baseline 5.91 ± 6.59 6.41 ± 5.07 0.685 0.463
Depressive symptoms 7 days 5.67 ± 5.19 6.13 ± 6.88 0.709 0.241
Anxiety symptoms baseline 4.75 ± 2.81 5.28 ± 4.03 0.739 0.945
Anxiety symptoms 7 days 3.90 ± 2.87 5.61 ± 4.32 0.064 0.119
Positive affect baseline 35.25 ± 5.74 34.97 ± 4.81 0.548 0.128
Positive affect 7 days 32.73 ± 7.19 33.97 ± 6.01 0.385 0.230
*statistically significant (p < 0.05)
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suggest is that the alterations in cortisol slope seen in the
female escitalopram group were being driven by increases in
waking cortisol levels.
Because men receiving escitalopramwere somewhat younger
on average thanmen receiving placebo, sensitivity analyses were
carried out with age included as a covariate in the male-only
analyses. ANCOVA revealed no significant main effects of drug
on any of the cortisol parameters (all p values > 0.05).
Discussion
The aim of this study was to assess the effects of six-day admin-
istration of escitalopram on several different indices of diurnal
HPA axis function in healthy volunteers. This was the first study
to examine the effects of SSRIs on cortisol slope, CAR, and
AUC in healthy volunteers. This permitted the measurement of
the direct effects of SSRIs on diurnal cortisol secretion indepen-
dent of symptom remission or changes in mood. We
hypothesised that escitalopram would lead to changes in the
CAR, the cortisol AUC, and the cortisol slope, and, more specif-
ically, that escitalopramwould bring about an increase in waking
cortisol levels. We also postulated that sex would influence the
effects of escitalopram on cortisol. The results of this study pro-
vide some support for these hypotheses. Comparedwith placebo,
women taking escitalopram had significantly steeper cortisol
slopes across the day. This difference was independent of any
differences in stress- or mood-related factors, suggesting that the
observed results were due to direct biological effects of
escitalopram on HPA axis function. In line with our hypothesis,
this alteration in cortisol slope seen in women taking
escitalopram was driven by an increase in waking levels of cor-
tisol. Six-day administration of escitalopram did not have a sig-
nificant effect on the cortisol AUC or the CAR.
It is difficult to compare our results with previous work
directly, because almost all studies have assessed effects of
SSRIs on HPA axis function in clinical populations. Cortisol
AUC and the CAR are known to be altered in depression
(Marchand et al. 2014; Dedovic and Ngiam 2015). Our study
involved healthy volunteers which may explain why we did
not observe any significant effects on overall daily cortisol
output or on the CAR. However, we did find that escitalopram
brought about a steepening of the cortisol slope in
healthy women and that this was likely driven by increases
in waking cortisol levels. This finding is supported by the
work of Harmer et al. (2003) who found that six-day admin-
istration of citalopram (20 mg/day) brought about significant







































Fig. 1 Escitalopram versus placebo. Mean salivary cortisol values across
the day in (a)men and (b)women. Saliva samples were taken on waking,
waking + 30 min, 10 a.m., noon, 4 p.m., 8 p.m., and at bedtime in healthy
volunteers who received six days treatment with escitalopram (black
line), or placebo (grey line). Error bars represent SEM
Table 2 Mean diurnal cortisol
parameter values Escitalopram Placebo Escitalopram vs. placebo
Diurnal cortisol parameters Mean ± SD Mean ± SD Group p
value
Group × sex p
value
Waking cortisol (nmol/L) (n = 61) 25.16 ± 12.83 18.67 ± 13.34 0.071 0.104
Bedtime cortisol (nmol/L) (n = 62) 5.99 ± 9.68 6.31 ± 8.76 0.836 0.092
Average evening cortisol (nmol/L)
(n = 62)
6.41 ± 5.87 6.58 ± 5.29 0.904 0.085
Cortisol AUC (nmol/L) (n = 59) 209.57 ± 82.49 188.31 ± 71.82 0.225 0.676
CAR (nmol/L) (n = 52) 7.63 ± 12.26 13.07 ± 14.85 0.440 0.221
Cortisol slope (nmol/L/min)
(n = 62)
0.0219 ± 0.0239 0.0153 ± 0.0224 0.378 0.023*
*statistically significant (p < 0.05)
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Interestingly, in depressed patients, SSRIs have been found to
lower waking cortisol levels (Knorr et al. 2012; Ruhé et al.
2015). Since waking cortisol levels may be increased in de-
pression (Bhagwagar et al. 2005), the direction of the effect of
SSRIs on waking cortisol could be related to mental health
status.
Mechanistically, there are a number of ways in which
escitalopram could have altered HPA axis function in women
in the current study. The serotonergic system has been found to
exert substantial effects onHPA axis function (Porter et al. 2004).
5-HT receptor agonists are known to induce cortisol secretion in
both human (Pitchot et al. 2004) and murine studies (Mikkelsen
et al. 2004). Therefore, SSRI-induced increases in serotonin
might bring about changes in cortisol secretion via the serotoner-
gic receptors. In fact, immunohistochemical studies have shown
that 5-HT receptors are present on the paraventricular nucleus of
the hypothalamus which is responsible for the release of
corticotropin-releasing hormone (CRH)—the initial effector of
the HPA axis (Lanfumey et al. 2008). Melatonin—a hormone
involved in regulating sleeping and waking cycles—has been
shown to affect 5-HT receptor-mediated activation of the HPA
axis (Raghavendra and Kulkarni 2000). SSRIs increase melato-
nin levels in depressed patients (Carvalho et al. 2009). Therefore,
SSRI-induced changes in melatonin levels might explain the
alterations in waking cortisol levels in the current study.
Escitalopram may have also exerted direct effects on HPA
axis function. A growing body of research suggests that SSRIs
may affect the HPA axis via modulation of the corticosteroid
receptors. Four days treatment with citalopram has been
shown to increase both glucocorticoid and mineralocorticoid
receptor sensitivity in healthy humans (Pariante et al. 2004,
2012). Flatter cortisol slopes have been associated with re-
duced GR sensitivity (Jarcho et al. 2013). It is possible that
the steeper cortisol slope seen in women taking escitalopram
in the current study is a result of increased sensitivity of the
corticosteroid receptors.
Steeper slopes were only observed in women taking
escitalopram. There are a number of reasons why this might
be. Firstly, there are known sex differences in HPA axis func-
tion (Bale and Epperson 2015). Women have been shown to
have increased diurnal cortisol secretion (Carpenter et al.
2015), and higher oestrogen levels have also been associated
with higher morning cortisol peaks (Wolfram et al. 2011). This
may be why we observed higher CARs in women in the cur-
rent study, independent of the effects of the study medications.
Women have been shown previously to have higher CARs
compared with men (Kunz-Ebrecht et al. 2004). Male steroi-
dal sex hormones also appear to play a role in cortisol secre-
tion. For example, testosterone is known to decrease cortico-
sterone in rats (Panagiotakopoulos and Neigh 2014).
Secondly, the sex difference observed in the current study
may be related to 5-HT1A receptor expression. Stimulation of
the 5-HT1A receptor increases cortisol secretion (Pitchot et al.
2004). It may be that female HPA axis function is more re-
sponsive to increased levels of serotonin due to enhanced
receptor stimulation. According to Goel and colleagues,
oestrogen potentiates 5-HT1A receptor stimulation of the
HPA axis, whereas testosterone decreases it (Goel et al.
2014). This may explain the increases in waking cortisol seen
in the women receiving escitalopram. In further support of
this, research has shown that the level of 5-HT1A receptor
mRNA in the pituitary gland is almost seven times higher in
women (Goel and Bale 2010).
Finally, women with depression are thought to have more
favourable therapeutic responses to SSRIs. A review of 15
RCTs revealed that female depressed patients on the whole
are more responsive to SSRI treatment than male patients in
terms of symptom remission (Khan et al. 2005). There is also
evidence for a role of oestrogen in the sex differences seen in
therapeutic responses to SSRIs (Damoiseaux et al. 2014).
In terms of therapeutic implications, as mentioned previ-
ously, flatter cortisol slopes have been observed in depression
(Sjögren et al. 2006; Jarcho et al. 2013; Doane et al. 2013).
Although no changes in stress or mood factors were observed,
the steepening of the cortisol slope observed in women taking
SSRIs in the current study may be one of the mechanisms
through which these drugs exert their therapeutic effects.
HPA axis changes might precede mood effects. This area war-
rants further investigation, and future studies should take sex
differences into consideration.
A strength of this study is that it was a randomised placebo-
controlled double-blind trial. The study had a retention rate of
91.4% with 64 participants providing usable data on some
parameters of diurnal cortisol secretion. However, it is possi-
ble that this study was underpowered to detect certain effects.
There were more women than men in the current study, mean-
ing that we may have lacked sufficient statistical power to
detect drug effects in men. We included women in the study
who were taking hormonal contraception which is known to
affect cortisol secretion (Kirschbaum et al. 1999). This may
have impacted results. However, there was no difference in
contraception use between the two experimental conditions.
Additionally, our sample was largely composed of healthy
university students from high socioeconomic backgrounds.
Therefore, the results may not be readily generalizable to other
groups, or to clinical groups with depression. Cortisol was
measured over a single day, meaning that the diurnal secretion
may have been affected by situational factors rather than long-
term factors. However, we measured cortisol over the course
of a weekday which may help counteract the effects of single-
day sampling as most people have established weekday rou-
tines. Nevertheless, this measurement issue should be borne in
mind while interpreting results.
In conclusion, the results of this study indicate that six-day
treatment with the SSRI escitalopram brings about a steepen-
ing of cortisol slopes in healthy women, via increases in
3420 Psychopharmacology (2018) 235:3415–3422
waking cortisol levels. Flattened cortisol rhythms have been
seen in depression. This finding suggests that SSRIsmay exert
their therapeutic effects in women via correction of a flattened
diurnal cortisol rhythm.
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